July to September
- Net sales amounted to MSEK 0 (0)
- Net loss was MSEK -5.3 (-6.1), corresponding to earnings per share of SEK -0.09 (-0.11)
- Cash flow after financing activities amounted to MSEK -6.1 (+39.1)
- Cash amounted to MSEK 23.5 (52.1), compared to MSEK 45.3 on 31 December 2021
January to September
- Net sales amounted to MSEK 0 (0)
- Net loss was MSEK -19.9 (-21.1), corresponding to earnings per share of SEK -0.33 (-0.49)
- Cash flow after financing activities amounted to MSEK -21.8 (-27.9)
Significant events during January – September
- In January 2022, warrants corresponding to a dilution of 0.2% of the number of outstanding shares were deregistered.
- In February 2022, the first trial person was enrolled in PHSU05 (ensereptide).
- The recruitment target for the study was achieved according to plan in March.
- At the AGM in May, Marianne Dicander Alexandersson was elected new chairman of the board. Also, Candice Jung was elected new member of the board.
- In September 2022, the last clinic visit in PHSU05 occurred (ensereptide).
- In August 2022, the company received a granted patent in the European Union for the use of the candidate drug ropo-camptide (LL-37) for the treatment of chronic wounds.
Events after the reporting period
- In November 2022, it was announced that results from PHSU05 are expected in April 2023, where the lack of special-ized staff and equipment is the reason for the slight delay
”The third quarter of the year has been characterized by continued progress within our two clinical development programs”
Jonas Ekblom, President and CEO of Promore Pharma